NCT06178055 - A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

March 3, 2025

Study Completion Date

December 31, 2025

Conditions

Central Retinal Artery Occlusion

Interventions

DRUG

KUS121 high dose

Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

DRUG

KUS121 low dose

Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

DRUG

Sham procedure

Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

Trial Locations (11)

NYEE Infirmary of Mount Sinai, New York

Cumberland Valley Retina Consultants, Hagerstown

Florida Retina Institute, Jacksonville

UH Eye Institute, Cleveland

Kresge Eye Institute/Wayne State University, Detroit

Retina Consultants of Texas, The Woodlands

Retina Consultants of Texas, San Antonio

Austin Retina Associates, Austin

The Retina Partners, Encino

Salehi Retina Institute, Inc, Huntington Beach

Kaiser Permanente Oakland Med Ctr., Oakland